Special Drug Use-Results Survey for ACTAIR Sublingual Tablets (Long-term Use)

Special Drug Use-Results Survey for ACTAIR Sublingual Tablets (Long-term Use) - Special Drug Use-Results Survey for ACTAIR Sublingual Tablets (Long-term Use)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042840

Enrollment

500

Registered

2020-12-24

Start date

2015-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis due to house dust mites

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with allergic rhinitis due to house dust mites who administrate ACTAIR for the first time

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Adverse events at long-term use (up to 4 years)	—

Secondary

Measure	Time frame
Assessment of severity of allergic rhinitis (at enrollment, 6 months later, 1 year later, 2 years later, 3 years later, 4 years later and at discontinuation) and patients' global evaluation (6 months later, 1 year later, 2 years later, 3 years later, 4 years later, at discontinuation and 1 year after discontinuation) at long-term use (up to 4 years)	—

Countries

Japan

Contacts

Public ContactYuta Asaka

Shionogi & Co., Ltd. Pharmacovigilance Department

yuta.asaka@shionogi.co.jp+81-70-7812-6812

Outcome results